Recent discussions on X about Sutro Biopharma (STRO) have centered around a flurry of insider buying activity, sparking curiosity among investors. Posts on the platform highlight that multiple insiders, including high-ranking executives, have purchased significant shares in the past few days at notably low prices, with some transactions reported as recently as October 16, 2025. This has led to speculation about the company’s future prospects and whether these moves signal confidence in upcoming developments.
The conversation also touches on Sutro Biopharma’s stock performance, with some users noting a pre-market surge following the insider purchases, while others remain cautious due to past challenges like dilution and fundraising pressures. There’s a palpable tension between optimism for potential catalysts, such as key clinical data releases, and lingering concerns over the biotech sector’s volatility. These discussions reflect a broader interest in whether the current price represents a turning point for the company.
Note: This discussion summary was generated from an AI condensation of post data.
Sutro Biopharma Insider Trading Activity
Sutro Biopharma insiders have traded $STRO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STRO stock by insiders over the last 6 months:
- CONNIE MATSUI purchased 50,000 shares for an estimated $39,950
- GREGORY K. CHOW (CFO) purchased 19,750 shares for an estimated $15,997
- HANS-PETER GERBER (CHIEF SCIENTIFIC OFFICER) purchased 17,000 shares for an estimated $13,606
- JANE CHUNG (Chief Executive Officer) purchased 12,500 shares for an estimated $10,011
- DAVID PAULING (Chief Admin. Ofcr. & GC) purchased 12,504 shares for an estimated $9,993
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Sutro Biopharma Hedge Fund Activity
We have seen 50 institutional investors add shares of Sutro Biopharma stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,434,637 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,165,887
- BLACKROCK, INC. removed 4,097,776 shares (-66.0%) from their portfolio in Q2 2025, for an estimated $2,925,402
- MILLENNIUM MANAGEMENT LLC added 4,029,088 shares (+573.0%) to their portfolio in Q2 2025, for an estimated $2,876,365
- TANG CAPITAL MANAGEMENT LLC added 2,361,586 shares (+1180.8%) to their portfolio in Q2 2025, for an estimated $1,685,936
- VELAN CAPITAL INVESTMENT MANAGEMENT LP added 2,030,000 shares (+197.1%) to their portfolio in Q2 2025, for an estimated $1,449,217
- UBS GROUP AG added 1,543,313 shares (+2042.2%) to their portfolio in Q2 2025, for an estimated $1,101,771
- STATE STREET CORP removed 1,339,687 shares (-79.6%) from their portfolio in Q2 2025, for an estimated $956,402
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Sutro Biopharma Analyst Ratings
Wall Street analysts have issued reports on $STRO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/16/2025
- B of A Securities issued a "Underperform" rating on 05/19/2025
To track analyst ratings and price targets for Sutro Biopharma, check out Quiver Quantitative's $STRO forecast page.
Sutro Biopharma Price Targets
Multiple analysts have issued price targets for $STRO recently. We have seen 4 analysts offer price targets for $STRO in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $3.0 on 08/12/2025
- Edward Tenthoff from Piper Sandler set a target price of $2.0 on 06/16/2025
- Tazeen Ahmad from B of A Securities set a target price of $0.8 on 05/19/2025
- Andres Maldonado from HC Wainwright & Co. set a target price of $2.0 on 04/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
